{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:24:30Z","timestamp":1740108270825,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00198-016-3567-x","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T11:32:15Z","timestamp":1458300735000},"page":"2627-2629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multiple cranial neuropathies following zoledronic acid infusion: a relationship? Clinical features and pathogenic discussion concerning a case"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8887-3233","authenticated-orcid":false,"given":"S.","family":"Deshayes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Martin Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cogez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Baldolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fedrizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Bienvenu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Aouba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"key":"3567_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23\u201357. doi: 10.1007\/s00198-012-2074-y","journal-title":"Osteoporos Int"},{"key":"3567_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/rheumatology\/ket236","volume":"53","author":"E Suresh","year":"2014","unstructured":"Suresh E, Pazianas M, Abrahamsen B (2014) Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology 53:19\u201331. doi: 10.1093\/rheumatology\/ket236","journal-title":"Rheumatology"},{"key":"3567_CR3","first-page":"111","volume":"40","author":"B B\u00e9gaud","year":"1985","unstructured":"B\u00e9gaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 40:111\u2013118","journal-title":"Therapie"},{"key":"3567_CR4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245","journal-title":"Clin Pharmacol Ther"},{"key":"3567_CR5","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1182\/blood-2011-01-328526","volume":"118","author":"O Nussbaumer","year":"2011","unstructured":"Nussbaumer O, Gruenbacher G, Gander H, Thurnher M (2011) DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by \u03b3\u03b4 T lymphocytes. Blood 118:2743\u20132751. doi: 10.1182\/blood-2011-01-328526","journal-title":"Blood"},{"key":"3567_CR6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s002239900353","volume":"61","author":"D Thi\u00e9baud","year":"1997","unstructured":"Thi\u00e9baud D, Sauty A, Burckhardt P et al (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386\u2013392","journal-title":"Calcif Tissue Int"},{"key":"3567_CR7","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.bone.2012.02.006","volume":"50","author":"AD Anastasilakis","year":"2012","unstructured":"Anastasilakis AD, Polyzos SA, Makras P et al (2012) Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone 50:1130\u20131134. doi: 10.1016\/j.bone.2012.02.006","journal-title":"Bone"},{"key":"3567_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/annonc\/mdl298","volume":"18","author":"D Santini","year":"2007","unstructured":"Santini D, Vincenzi B, Caraglia M, Tonini G (2007) A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. Ann Oncol 18:201\u2013202. doi: 10.1093\/annonc\/mdl298","journal-title":"Ann Oncol"},{"key":"3567_CR9","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/art.39204","volume":"67","author":"JC Hall","year":"2015","unstructured":"Hall JC, Baer AN, Shah AA et al (2015) Molecular subsetting of interferon pathways in Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol 67:2437\u20132446. doi: 10.1002\/art.39204","journal-title":"Arthritis Rheumatol"},{"key":"3567_CR10","first-page":"295","volume":"11","author":"R Gerli","year":"1993","unstructured":"Gerli R, Agea E, Muscat C et al (1993) Functional characterization of T cells bearing the gamma\/delta T-cell receptor in patients with primary Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol 11:295\u2013299","journal-title":"Clin Exp Rheumatol"},{"key":"3567_CR11","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s004150050492","volume":"246","author":"E Touz\u00e9","year":"1999","unstructured":"Touz\u00e9 E, Blanche P, Zuber M (1999) A 35-year history of recurrent multiple cranial neuropathy due to primary Sj\u00f6gren\u2019s syndrome. J Neurol 246:968\u2013969","journal-title":"J Neurol"},{"key":"3567_CR12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0300-483X(99)00141-9","volume":"142","author":"T Vial","year":"2000","unstructured":"Vial T, Choquet-Kastylevsky G, Liautard C, Descotes J (2000) Endocrine and neurological adverse effects of the therapeutic interferons. Toxicology 142:161\u2013172","journal-title":"Toxicology"},{"key":"3567_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s10156-012-0383-x","volume":"18","author":"G Mellon","year":"2012","unstructured":"Mellon G, Stitou H, Aoun O et al (2012) Lateral rectus muscle paralysis induced by ribavirin and pegylated interferon-\u03b12a in a patient with HIV\/HCV co-infection. J Infect Chemother 18:937\u2013938. doi: 10.1007\/s10156-012-0383-x","journal-title":"J Infect Chemother"},{"key":"3567_CR14","first-page":"U1888","volume":"119","author":"R Stack","year":"2006","unstructured":"Stack R, Tarr K (2006) Drug-induced optic neuritis and uveitis secondary to bisphosphonates. N Z Med J 119:U1888","journal-title":"N Z Med J"},{"key":"3567_CR15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02238770","volume":"16","author":"JM Des Grottes","year":"1997","unstructured":"Des Grottes JM, Schrooyen M, Dumon JC, Body J-J (1997) Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria. Clin Rheumatol 16:93\u201395","journal-title":"Clin Rheumatol"},{"key":"3567_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.clon.2012.12.006","volume":"25","author":"P Brulinski","year":"2013","unstructured":"Brulinski P, Nikapota AD (2013) Zolendronic acid-induced retrobulbar optic neuritis: a case report. Clin Oncol 25:328\u2013329. doi: 10.1016\/j.clon.2012.12.006","journal-title":"Clin Oncol"},{"key":"3567_CR17","first-page":"434","volume":"65","author":"S Lespagnard","year":"2010","unstructured":"Lespagnard S, Bonnet S, Betz P (2010) Clinical case of the month. Bilateral optic neuropathy secondary to biphosphonate therapy. Rev Med Liege 65:434\u2013436","journal-title":"Rev Med Liege"},{"key":"3567_CR18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9394(02)01840-8","volume":"135","author":"FW Fraunfelder","year":"2003","unstructured":"Fraunfelder FW, Fraunfelder FT, Jensvold B (2003) Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 135:219\u2013222","journal-title":"Am J Ophthalmol"},{"key":"3567_CR19","first-page":"97","volume":"43","author":"Y Zadik","year":"2012","unstructured":"Zadik Y, Benoliel R, Fleissig Y, Casap N (2012) Painful trigeminal neuropathy induced by oral bisphosphonate-related osteonecrosis of the jaw: a new etiology for the numb-chin syndrome. Quintessence Int 43:97\u2013104","journal-title":"Quintessence Int"},{"key":"3567_CR20","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1016\/j.lpm.2012.06.002","volume":"41","author":"A-L Fauchais","year":"2012","unstructured":"Fauchais A-L, Magy L, Vidal E (2012) Central and peripheral neurological complications of primary Sj\u00f6gren\u2019s syndrome. Presse Med 41:e485\u2013e493. doi: 10.1016\/j.lpm.2012.06.002","journal-title":"Presse Med"},{"key":"3567_CR21","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1093\/brain\/awh605","volume":"128","author":"K Mori","year":"2005","unstructured":"Mori K (2005) The wide spectrum of clinical manifestations in Sjogren\u2019s syndrome-associated neuropathy. Brain 128:2518\u20132534. doi: 10.1093\/brain\/awh605","journal-title":"Brain"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3567-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-016-3567-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3567-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:15:33Z","timestamp":1558610133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-016-3567-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["3567"],"URL":"https:\/\/doi.org\/10.1007\/s00198-016-3567-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2016,3,15]]}}}